Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Amortization of Deferred Charges: 2013-2025

Historic Amortization of Deferred Charges for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to $758,000.

  • Ocular Therapeutix's Amortization of Deferred Charges rose 22.06% to $758,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 26.17%. This contributed to the annual value of $3.7 million for FY2024, which is 38.85% down from last year.
  • Per Ocular Therapeutix's latest filing, its Amortization of Deferred Charges stood at $758,000 for Q3 2025, which was up 7.06% from $708,000 recorded in Q2 2025.
  • Ocular Therapeutix's 5-year Amortization of Deferred Charges high stood at $2.1 million for Q3 2023, and its period low was $569,000 during Q2 2024.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $1.2 million (2023), whereas its average is $1.2 million.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first spiked by 69.14% in 2023, then crashed by 70.03% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Amortization of Deferred Charges (Quarterly) stood at $1.2 million in 2021, then rose by 4.12% to $1.2 million in 2022, then climbed by 25.55% to $1.6 million in 2023, then tumbled by 62.91% to $576,000 in 2024, then climbed by 22.06% to $758,000 in 2025.
  • Its last three reported values are $758,000 in Q3 2025, $708,000 for Q2 2025, and $1.4 million during Q1 2025.